Pre-made Vunakizumab benchmark antibody ( Whole mAb, anti-IL17A/IL17 therapeutic antibody, Anti-CTLA-8/CTLA8A/ILA17 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Vunakizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vunakizumab is a recombinant humanized IgGκ monoclonal antibody binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-633-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Vunakizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
INN Name	Vunakizumab
Target	IL17
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Atridia;Jiangsu Hengrui Medicine Co.
Conditions Approved	na
Conditions Active	Plaque psoriasis;Psoriasis;Spondylarthritis
Conditions Discontinued	Autoimmune disorders
Development Tech	na